Please ensure Javascript is enabled for purposes of website accessibility

Study: Pfizer and BioNTech Vaccine Neutralizes Brazil Coronavirus Variant

By Eric Volkman - Mar 9, 2021 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The two companies' BNT162b2 seems to protect patients against the fast-spreading variant.

More good news for a world ravaged and exhausted by the coronavirus pandemic. BNT162b2, the vaccine developed by Pfizer (PFE 1.43%) and BioNTech (BNTX 5.66%), demonstrated that it can neutralize a threatening new variant of the coronavirus. The results of a recent laboratory study testing the vaccine against the P.1 variant were published in the New England Journal of Medicine on Monday. This variant is also known as Brazil because it's spreading rapidly through the massive South American country.

The study, conducted by Pfizer and BioNTech in cooperation with the University of Texas, found that BNT162b2 was effective against a version of the coronavirus engineered with mutations similar to those found on the P.1 variant.

Child getting a jab from a medical professional.

Image source: Getty Images.

While this development is certainly encouraging, the coronavirus continues to spread, spin off variants, and cause fatalities. As a result, Pfizer and BioNTech are remaining cautious. Pfizer said it will test a third booster shot of the vaccine, which is currently being administered in a two-dose regimen. The company added that it aims to put a retooled version of BNT162b2 specifically targeting another worrying variant, the so-called South Africa variant. 

In December, BNT162b2 was the first coronavirus vaccine to garner Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). It is still being widely distributed and administered along with No. 2, Moderna's mRNA-1273. Late last month, Johnson & Johnson's one-shot vaccine was granted the third EUA from the U.S. regulator.

Shares of both Pfizer and BioNTech rose on Tuesday. Pfizer's 0.3% bump lagged behind the 1.4% gain of the S&P 500 index, but BioNTech handily topped the benchmark with a 6.9% gain.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$51.40 (1.43%) $0.72
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.48 (0.23%) $0.40
Moderna, Inc. Stock Quote
Moderna, Inc.
$143.33 (5.19%) $7.07
BioNTech SE Stock Quote
BioNTech SE
$159.76 (5.66%) $8.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.